What is Revanesse?
Prollenium Medical Technologies, the parent entity behind Revanesse, operates at the intersection of biotechnology and aesthetic enhancement. The company specializes in the engineering and manufacturing of advanced dermal fillers, such as Revanesse Versa+ and Revanesse Lips+, which are clinically indicated for the correction of moderate to severe facial wrinkles and lip augmentation. By maintaining a rigorous focus on safety, efficacy, and regulatory compliance, the organization serves a critical role in providing healthcare providers with reliable tools for patient-centric aesthetic outcomes. Their market position is defined by a commitment to innovation in cross-linking technology, ensuring that their product portfolio meets the evolving demands of the global cosmetic dermatology market.
How much funding has Revanesse raised?
Revanesse has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Revanesse
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for Revanesse?
With the infusion of this latest capital, Revanesse is poised to enter a new phase of commercial scaling and market penetration. The strategic allocation of these funds will likely prioritize the expansion of distribution networks and the enhancement of manufacturing capabilities to meet the rising global demand for non-surgical aesthetic procedures. Furthermore, the company is expected to invest in clinical research and physician education programs, which are essential for maintaining high standards of patient safety and product adoption. As the aesthetic industry continues to shift toward minimally invasive solutions, Revanesse is strategically aligned to capture additional market share, leveraging its established reputation for quality and its strengthened balance sheet to navigate the complexities of the late-stage growth environment.
See full Revanesse company page
